The company is riding an incredible tailwind.

After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of ...

Eli Lilly exhibits strong bullish technicals, with price action, momentum, and relative strength all supporting a continued ...

Federal ethics disclosures published recently show President Donald Trump’s accounts purchased Eli Lilly stock on at least seven occasions in the first quarter of 2026 — a period in which his ...

The recent Lilly stock bounce has created a seasonal selling opportunity despite pricing headwinds and a rich valuation.

Eli Lilly (LLY) stock is back in focus after the company reported a very strong Q1, raised its full year revenue and earnings ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

On May 14, the federal government released ethics disclosures revealing a list of stock and bond trades made on Trump’s ...

Eli Lilly (NYSE: LLY) has become the leader in a market marching toward the $100 billion mark. I'm talking about the ...

Eli Lilly (LLY) has cemented its status as the world's leading pharmaceutical company as it produced a stellar set of Q1 2026 earnings. Net income increased 155% to $7.66bn, and for good measure, the ...

After losing its market edge to Eli Lilly (NYSE: LLY) despite its first-mover advantage in weight-loss drugs, Novo Nordisk is ...

And he may be right.